The Evolution of Comprehensive AIDS Clinical Care

The AIDS Pandemic

Volumn , Issue , 2005, Pages 261-285

  Mayer, Kenneth H ^a,b   Chaguturu, Sreekanth K ^c  

^a BROWN UNIVERSITY   (United States)

^b Fenway Community Health   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882829781     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012465271-2/50013-3     Document Type: Chapter

References (44)

1. American Academy of HIV Medicine (accessed 6 October 2003). http://www.aahivm.org/new/index.html.
2. Highlights in Transfusion Medicine History 2003, (acc essed 17 October 2003), American Association of Blood BanksAmerican Association of Blood Banks. http://www.aabb.org/All_About_Blood/FAQs/aabb_faqs.htm.
3. A Hospital-Wide Approach to AIDS 1983, December 1983, American Hospital AssociationAmerican Hospital Association, Advisory Committee on Infections within Hospitals.
4. Angerer T, Wilson D, Ford N, Kasper T Access and activism: the ethics of providing antiretroviral therapy in developing countries. AIDS 2001, 15(Suppl 5):S81-S90.
5. Arno PS, Feiden KL Against the Odds: The story of AIDS Drug Development, Politics and Profit 1992, Harper Collins, New York.
6. Baudiere S, Aceti A, D'Offizi GP, et al. Directly observed therapy to treat HIV infection in prisoners. JAMA 2000, 284:179-180.
7. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998, 339:1897-1904.
8. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001, 344:817-823.
9. Carton B New AIDS drug brings hope to Provincetown, but unexpected woes. Wall Street Journal 1996, A1. 3 October 1996.
10. Casarett DJ, Lantos JD Have we treated AIDS too well? Rationing and the future of AIDS exceptionalism. Ann Intern Med 1998, 128:756-759.
11. CDC Acquired immune deficiency syndrome (AIDS): precautions for clinical and laboratory staffs. MMWR Morbid Mortal Wkly Rep 1982, 32:577-580.
12. CDC Recommendations for preventing transmission of infection with HTLV-III/LAV in the workplace. MMWR 1985, 34:681-695.
13. CDC Recommendations for preventing transmission of infection with HTLV-III/LAV during invasive procedures. MMWR 1986, 35:221-223.
14. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002, 12:305-307.
15. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002, 12:312-316.
16. College of American Pathologists Proceedings of the Task Force on AIDS 1983.
17. Collier AC, Coombs RW, Schoenfeld DA, et al. The AIDS Clinical Trials Group treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1018.
18. Conte JE, University of California San Francisco Task Force on the Acquired Immunodeficiency Syndrome, et al. Special report: infection control guidelines for patients with the acquired immunodeficiency syndrome (AIDS). N Engl J Med 1983, 309:740-744.
19. Dubé MP, Stein JH, Aberg JA, et al. Cardiovascular subcommittee guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (hiv) infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627. Adult AIDS Clinical Trials Group.
20. Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001, 358:404-409.
21. Fischl M, Castro J, Mondoig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials (abstract 528). Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago) 2001, 202. Foundation for Retrovirology and Human Health, Alexandria, VA.
22. Goodman E For doctors, an AIDS dilemma that's spreading with the disease. Boston Globe 1988, 25 February.
23. Grossman BJ, Springer KM Blood donor deferral registries: highligts of a conference. Transfusion 1992, 32:868-872.
24. Hardy AM, et al. The economic impact of the first 10000 cases of acquired immunodeficiency syndrome in the United States. JAMA 1986, 255:209-215.
25. HIV Quality Care network: HIV provider Definitions 2003, (accessed 6 October 2003), HIV Medicine AssociationHIV Medicine Association. http://www.hivma.org/HIV/HIVnet_ProDef.htm.
26. Infectious Diseases Society of America (accessed 6 October 2003), HIV Medicine AssociationHIV Medicine Association. http://www.idsociety.org/HIV/HIVMA/Announce_9-00.htm.
27. Kaiser Family Foundation (accessed 17 January 2003). http://www.headlines.kff.org/healthpollreport/feature8/media/feature.pdf .
28. Kievits T, van Gemen B, van Strijp D, et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991, 35:273-286.
29. Leland J The end of AIDS?. Newsweek 1996, 2 December.
30. Leoung GS, Feigal DW, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med 1990, 323:769-775.
31. McCullough J The Nation's Changing Blood Supply System. JAMA 1993, 269.
32. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
33. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
34. Mitty JS, McKenzie M, Stenzel M, et al. Modified directly observed therapy for treatment of human immunodeficiency virus [research letter]. JAMA 1999, 282:1334.
35. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T Directly observed therapy for the treatment of people with human immunodefiency virus infection: a work in progress. Clin Infect Dis 2002, 34:984-990.
36. National Alliance of State and Territorial AIDS Directors Fiscal Status Update of State AIDS Drug Assistance Programs: Preliminary Findings from an August 1996 National Survey of State AIDS Programs 1996, 9 September: Table 1, National Alliance of State and Territorial AIDS Directors, Washington, DC.
37. Pachl C, Todd JA, Kerm DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:446-454.
38. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
39. Stolberg SG White House dropsplan for Medicaid to cover cost of AIDS drugs for poor. New York Times 1997, 14. 9 December.
40. US Institute of Medicine Disease by disease toward national insurance: Report of a Panel on Implications of a Categorical Catastrophic Disease Approach to National Health Insurance 1973, National Academy of Sciences, Washington, DC.
41. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immuno deficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990, 322:941-949.
42. Wohl DA, Stephenson BL, Golin CE, et al. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis 2003, 36:1572-1576.
43. WHO Scaling up antiretroviral therapy in resource limited settings: guidelines for a public health approach. Available at 2002, http://www.who.int.
44. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.